These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36712266)

  • 1. Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis.
    Cao F; Wu K; Zhu YZ; Jiang JJ; Zhang G; Liu J; Xiao P; Tian Y; Zhang W; Zhang S; Hou F; Bao ZW
    Front Cardiovasc Med; 2022; 9():1055897. PubMed ID: 36712266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 4. The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis.
    Shu T; Chen H; Wang L; Wang W; Feng P; Xiang R; Wen L; Huang W
    Front Pharmacol; 2021; 12():668902. PubMed ID: 33967811
    [No Abstract]   [Full Text] [Related]  

  • 5. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J; Gao Y; Deng B; Liu K
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials.
    Zhang Q; Xu B; Lv J; Wang Z; Du J
    Cardiol Young; 2020 Dec; 30(12):1882-1889. PubMed ID: 33077013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Zhu HR; Kuang HY; Li Q; Ji XJ
    Front Cardiovasc Med; 2022; 9():915470. PubMed ID: 35983180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
    Lei Y; Zhang X; Lin H; Feng Y; Wang J; Luo R
    Mod Rheumatol; 2021 Jan; 31(1):151-161. PubMed ID: 31829087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry.
    Garcia AR; Blanco I; Ramon L; Pérez-Sagredo J; Guerra-Ramos FJ; Martín-Ontiyuelo C; Tura-Ceide O; Pastor-Pérez F; Escribano-Subías P; Barberà JA
    Respir Res; 2023 Sep; 24(1):223. PubMed ID: 37715261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
    Chen Y; Li F; Luo J; Chen J; Luo P; Li J
    Can Respir J; 2021; 2021():1626971. PubMed ID: 34512819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.
    Gao XF; Zhang JJ; Jiang XM; Ge Z; Wang ZM; Li B; Mao WX; Chen SL
    Patient Prefer Adherence; 2017; 11():871-885. PubMed ID: 28507431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.